Importance Most clinical trials assessing systemic immunomodulatory treatments for patients
with atopic dermatitis are placebo-controlled. Objective To compare the effectiveness and …

With the increasing number of options for the treatment of moderate‐to‐severe atopic
dermatitis, clinicians need guidance on a practical approach to selecting a systemic agent …

Importance Systemic treatments for atopic dermatitis are being evaluated primarily in
placebo-controlled trials; network meta-analysis can provide relative efficacy and safety …

Atopic dermatitis (AD) is a multifaceted, chronic relapsing inflammatory skin disease that
affects people of all ages. It is characterized by chronic eczema, constant pruritus, and …

Background Food allergy continues to pose problems due to its increased frequency and its
increasingly high severity. In this context, alongside the traditional avoidance strategies of …

Atopic dermatitis is characterised by itch (pruritus), characteristic morphology and
distribution, a chronic relapsing course, and high personal and social disease burden. 1 The …

Background Clinical trials of systemic therapies for atopic dermatitis (AD) often exclude
patients based on age and comorbidities. Objectives We conducted a scoping review of …

Background: Some Network Meta-analysis (NMA) has been published regarding atopic
dermatitis (AD). These studies have considered drugs under investigation both in …

Abstract Background The TREatment of ATopic eczema (TREAT) Registry Taskforce is a
collaborative international network of registries collecting data of atopic eczema (AE) …

The term “eczema” is derived from the Greek word “ekzein” meaning “to boil over.”
Dermatitis, a synonymous term, refers to conditions with spongiotic pathology. Acute …